You want a piece of Sovaldi, Roche? Not so fast

Gilead ($GILD) has successfully convinced a panel of arbitrators that competitor Roche ($RHHBY) has no legitimate claims on Sovaldi, its hep C blockbuster. Roche had argued that a 2004 collaboration with Pharmasset, later picked up by Gilead for $11 billion, gave the company a license to the product, putting it in line for a slice of the record-breaking sales haul Sovaldi has racked up since its launch earlier this year. But while Gilead may have put those claims to rest, it still faces patent tussles with a host of rivals looking to cash in on next-gen hep C combo therapies. More

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.